Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 93 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Otsuka Holdings Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Otsuka Holdings Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Otsuka Holdings Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Otsuka Holdings Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Otsuka Holdings Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Otsuka Holdings Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Otsuka Holdings Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Otsuka Holdings Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Otsuka Holdings Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Otsuka Holdings Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Otsuka Holdings Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Otsuka Holdings Co., Ltd. Snapshot 7
Otsuka Holdings Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Otsuka Holdings Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Otsuka Holdings Co., Ltd. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Otsuka Holdings Co., Ltd. - Pipeline Products Glance 17
Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Otsuka Holdings Co., Ltd. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Otsuka Holdings Co., Ltd. - Drug Profiles 22
(tipiracil + trifluridine) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
aripiprazole 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
brexpiprazole 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
tolvaptan 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
(aripiprazole + sertraline) 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
delamanid 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
nabiximols 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
OPC-1085EL 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rebamipide 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TAS-202 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
OCV-101 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
OCV-501 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
OPA-15406 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
probucol 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
tetomilast 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
trabectedin 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
OPA-6566 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
OPB-111001 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
OPB-31121 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GNX-8 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LPC-01 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
OCVC-02 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
OPB-111077 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
OPB-51602 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
OPC-108459 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
OPS-2071 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Progranulin 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Otsuka Holdings Co., Ltd. - Pipeline Analysis 62
Otsuka Holdings Co., Ltd. - Pipeline Products by Target 62
Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration 64
Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type 65
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action 66
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates 68
Otsuka Holdings Co., Ltd. - Dormant Projects 85
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products 86
Discontinued Pipeline Product Profiles 86
rebamipide 86
Otsuka Holdings Co., Ltd. - Locations And Subsidiaries 87
Head Office 87
Other Locations & Subsidiaries 87
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

List of Tables
Otsuka Holdings Co., Ltd., Key Information 7
Otsuka Holdings Co., Ltd., Key Facts 7
Otsuka Holdings Co., Ltd. - Pipeline by Indication, 2014 10
Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2014 12
Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2014 13
Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 14
Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2014 15
Otsuka Holdings Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 16
Otsuka Holdings Co., Ltd. - Pre-Registration, 2014 17
Otsuka Holdings Co., Ltd. - Phase III, 2014 18
Otsuka Holdings Co., Ltd. - Phase II, 2014 19
Otsuka Holdings Co., Ltd. - Phase I, 2014 20
Otsuka Holdings Co., Ltd. - Preclinical, 2014 21
Otsuka Holdings Co., Ltd. - Pipeline by Target, 2014 63
Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2014 64
Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2014 65
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 67
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates, 2014 68
Otsuka Holdings Co., Ltd. - Dormant Developmental Projects,2014 85
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products, 2014 86
Otsuka Holdings Co., Ltd., Subsidiaries 87